Brief: Allovir Initiates Phase 3 Registrational Study Of Posoleucel For Prevention Of Life-Threatening Viral Infections From Six Common Viruses In High-Risk Cell Transplant Patients

Kalaris Therapeutics

22/03/2022 11:22

March 22 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR INITIATES GLOBAL PHASE 3 REGISTRATIONAL STUDY OF
POSOLEUCEL FOR PREVENTION OF LIFE-THREATENING VIRAL INFECTIONS
FROM SIX COMMON VIRUSES IN HIGH-RISK, ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANT PATIENTS

Source text for Eikon:  ID:nBwc7x6Lca 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com;))